Patients lack access to life-saving TR treatment.
TR is a dreadful heart valve condition. If left untreated, it drastically impacts life expectancy and quality-of-life.
Tricuspid Regurgitation (TR) occurs when the tricuspid valve in the heart doesn’t close properly, causing blood to leak back from the right ventricle into the right atrium and body.
Studies show severe TR is associated with a 50% mortality rate within two years if left untreated, disproportionally affecting women (4.3x times more often).
Today, approximately 4.6 million European and US people suffer from TR, yet over 90% remains untreated, emphasizing a clear unmet clinical need.
Limited treatment options
Current management strategies for TR face limitations.
Medication
Provides symptomatic relief without addressing the root cause, potentially allowing disease progression and causing side effects.
Open-Heart Surgery
Carries high mortality risk (~15%-30%) and is rarely an option for secondary TR patients. <1% of those patients are treated surgically.
Transcatheter Interventions
While emerging, availability and adoption of current technologies are limited by barriers for patients and providers. Only 3% of severe and greater TR patients are treated with transcatheter interventions today.
Barriers to transcatheter treatment of TR
Existing transcatheter TR treatments only reach 3% of severe and greater TR patients, due to two type of barriers.
Patient barriers
Existing treatments fail to address the full TR population, as many patients present anatomical or imaging challenges—such as large coaptation gaps or leaflet tethering—that limit eligibility and puts patients at risk for suboptimal outcomes.
Provider barriers
Existing technologies are complex, costly and time-consuming. They require advanced imaging and highly specialized teams, confining their use to top-tier centers. Long procedural times, low cath-lab turnover and high costs hinder clinical uptake.
Over 90% of TR patients remain untreated due to patient and provider significant barriers.
Transcathether treatment
Transcatheter treatment reaches only 3% of severe and greater TR patients, due to patient and provider barriers.
Patients untreated
Each year, an estimated 318,000 people in the EU and US develop severe or greater TR. Without treatment, both quality of life and life expectancy are significantly reduced. Yet, over 90% of these patients remain untreated.
Patient barriers
- Large coaptation gap
- Leaflet anatomies
- Annular dimensions
- Imaging difficulties
- Ventricular dysfunction
- Pacemakers/other devices
- Failed prior repair
Provider barriers
- Procedural complexity
- Need for top tier & highly experienced physicians
- Advanced hospital equipment needs
- Advanced imaging needs
- Long procedure time (>120 minutes)
- Lengthy procedures limit cath-lab capacity
- High device & hospital stay costs
- Low reproducibility
Simple, safe, effective.
Simple, safe, effective.
Tripair is a minimally invasive solution restoring tricuspid valve function with precision, speed, and efficiency.
